Research design considerations for chronic pain prevention clinical trials
Jennifer S. Gewandter(University of Rochester), Gary A. Walco(Seattle Children's Hospital), Joel Katz(University Health Network), Richard Malamut(Teva Pharmaceuticals (Czechia)), Christine Rauschkolb(Johnson & Johnson (United States)), Clifford J. Woolf(Boston Children's Hospital), Bob A. Rappaport, Henrik Kehlet(Copenhagen University Hospital), Ernest A. Kopecky(Endo Pharmaceuticals (United States)), Ole Graff(GlaxoSmithKline (Netherlands)), Rachel A. Kitt(University of Rochester), John D. Markman(University of Rochester), Michael A. Ashburn(University of Pennsylvania), James P. Robinson(University of Minnesota), Steven Z. George(Duke University), Michael McDermott(Unknown), Robert H. Dworkin(University of Rochester Medical Center), Ilona Steigerwald(Grünenthal Group (Germany)), Jeffrey Tobias(Jazz Pharmaceuticals (United States)), Anne Louise Oaklander(Harvard University Press), Laurie B. Burke(Center for Drug Evaluation and Research), Roger B. Fillingim(University of Florida), Michael Polydefkis(Université Paris-Sud), John T. Farrar(Hospital of the University of Pennsylvania), Srinivasa N. Raja(Johns Hopkins University), Pamela Pierce Palmer(AcelRx Pharmaceuticals (United States)), Dan Ziegler(University of Würzburg), Smriti Iyengar(National Institute of Neurological Disorders and Stroke), Dennis C. Turk(University of Washington), Penney Cowan(American Chronic Pain Association), Ian Gilron(Apple (Israel)), Veeraindar Goli(Duke University), Gary W. Jay(North Carolina Virtual Public School)
Cited by 143
Related Papers
The biopsychosocial approach to chronic pain: Scientific advances and future directions.
|Psychological Bulletin|2007|3.3k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Neuropathic pain
|Nature Reviews Disease Primers|2017|2k